New HIV pill shows promise in early trial

NCT ID NCT06039579

Summary

This study tested two experimental oral drugs designed to block HIV by targeting the virus's capsid. It involved 44 adults with HIV who had never taken antiviral medication before. Participants received one of the drugs or a placebo for 10 days so researchers could measure how much the virus decreased and check the safety of the medications.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • GSK Investigational Site

    Bakersfield, California, 93301, United States

  • GSK Investigational Site

    DeLand, Florida, 32720, United States

  • GSK Investigational Site

    Newark, New Jersey, 07102, United States

  • GSK Investigational Site

    Buenos Aires, 1023, Argentina

  • GSK Investigational Site

    Buenos Aires, C1202ABB, Argentina

  • GSK Investigational Site

    Buenos Aires, C1425AGC, Argentina

  • GSK Investigational Site

    Ciudad Autonoma de Bueno, C1405CKC, Argentina

  • GSK Investigational Site

    Montreal, Quebec, H2L 4P9, Canada

  • GSK Investigational Site

    Marseille, 13003, France

  • GSK Investigational Site

    Nantes, 44093, France

  • GSK Investigational Site

    Paris, 75018, France

  • GSK Investigational Site

    Cologne, 50937, Germany

  • GSK Investigational Site

    Milan, 20157, Italy

  • GSK Investigational Site

    Guadalajara, 44160, Mexico

  • GSK Investigational Site

    Mexico City, 06760, Mexico

  • GSK Investigational Site

    Barcelona, 08907, Spain

  • GSK Investigational Site

    Barcelona, 08916, Spain

  • GSK Investigational Site

    Madrid, 28034, Spain

  • GSK Investigational Site

    Madrid, 28046, Spain

  • GSK Investigational Site

    London, SE5 8RX, United Kingdom

Conditions

Explore the condition pages connected to this study.